Hanmi Pharm. Co.

128940.KO

192.05 USD

-8.60

-4.29%

Overview

Last close

192.05 usd

Market cap

2.44B usd

52 week high

258.79 usd

52 week low

146.58 usd

Target price

259.39 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

2.309

Price/Book Value

3.1805

Enterprise Value

2.70B usd

EV/Revenue

2.5614

EV/EBITDA

14.0668

Key financials

Revenue TTM

1.05B usd

Gross Profit TTM

572.00M usd

EBITDA TTM

208.05M usd

Earnings per Share

N/A usd

Dividend

0.89 usd

Total assets

1.35B usd

Net debt

N/A usd

About

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.